Genzyme Faces Inventory Crunch As It Discards Poor Lots of Thymoglobulin
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturing issues plague Genzyme’s Thymoglobulin as its sales grow and firm studies additional indications.
You may also be interested in...
Genzyme Gets FDA Warning Letter On French Thymoglobulin Plant
Biotech received similar letter in 2004 questioning quality control practices.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.